Short Interest in Aeterna Zentaris Inc. (NASDAQ:AEZS) Drops By 46.6%

Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) saw a significant decrease in short interest in June. As of June 15th, there was short interest totalling 9,300 shares, a decrease of 46.6% from the May 31st total of 17,400 shares. Based on an average daily volume of 9,100 shares, the short-interest ratio is presently 1.0 days. Approximately 0.3% of the shares of the stock are sold short.

Aeterna Zentaris Stock Performance

Shares of AEZS opened at $4.42 on Friday. The company has a market capitalization of $7.93 million, a price-to-earnings ratio of -0.30 and a beta of 1.60. The company’s 50 day simple moving average is $7.48 and its 200 day simple moving average is $7.70. Aeterna Zentaris has a 1 year low of $3.96 and a 1 year high of $12.80.

Aeterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) last announced its quarterly earnings data on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.

Analysts Set New Price Targets

Separately, StockNews.com began coverage on shares of Aeterna Zentaris in a research note on Tuesday, June 25th. They set a “sell” rating on the stock.

Aeterna Zentaris Company Profile

Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.